Infection is common in patients treated with CD19-directed chimeric antigen receptor T-cell therapy, but it is not associated with higher mortality
-
-
FDA approves new drug for diffuse large B-cell lymphoma The approval is based on the phase 2 L-MIND trial.
-
FDA approves tafasitamab-cxix for R/R DLBCL The approval is based on the phase 2 L-MIND trial.
-
FDA okays new CAR T therapy, first for mantle cell lymphoma Approval is based on the ongoing ZUMA-2 trial.
-
FDA approves first CAR T therapy for R/R MCL The approval is based on the ongoing ZUMA-2 trial.
-
NICE: brentuximab vedotin for untreated sALCL Final draft guidance from NICE recommend brentuximab vedotin with CHP for untreated systemic anaplastic large cell lymphoma
-
Official figures from the Medicines and Healthcare products Regulatory Agency.
-
FDA approves tazemetostat and companion assay for R/R FL with EZH2 mutation The approval was based on an open-label, single-arm, phase 2 trial.
-
EHA 2020 – “Nordic” treatment of mantle cell lymphoma superior to CHOP, Swedish data show Nationwide data from Sweden show changes in treatment of mantle cell lymphomas.
-
EHA 2020 – UK successfully implements national structure for CAR-T cell therapy for high-grade lymphomas UK data confirm long-term benefit of CAR-T cell therapy for more than a third of patients.
-
EHA 2020 – Cross-trial comparison shows benefit of tafasitamab in patients with diffuse large B-cell lymphomas Will anti-CD19 activity improve responses rates in DLBCL? The answer is sought in a cross-trial comparison.
-
EHA 2020 – PET-guided treatment may allow many patients with Hodgkin lymphoma to avoid radiotherapy Four cycles of chemotherapy sufficient in patients responding to treatment.
-
Dose-adjusted EPOCH-R therapy is suitable for adults with Burkitt lymphoma Findings from a multicenter risk-adapted study.
-
ASCO 2020 – R/R Hodgkin lymphoma: pembrolizumab tops brentuximab for PFS in phase 3 PFS benefit was seen across all subgroups.